PL3027642T3 - Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) - Google Patents

Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)

Info

Publication number
PL3027642T3
PL3027642T3 PL14752711T PL14752711T PL3027642T3 PL 3027642 T3 PL3027642 T3 PL 3027642T3 PL 14752711 T PL14752711 T PL 14752711T PL 14752711 T PL14752711 T PL 14752711T PL 3027642 T3 PL3027642 T3 PL 3027642T3
Authority
PL
Poland
Prior art keywords
gdf
constructs
differentiation factor
growth differentiation
growth
Prior art date
Application number
PL14752711T
Other languages
English (en)
Inventor
Yumei Xiong
Yi Zhang
Jackie Z. Sheng
Agnes Eva Hamburger
Murielle Veniant-Ellison
Grant Shimamoto
Xiaoshan MIN
Zhulun Wang
Jie Tang
Gunasekaran Kannan
Marissa Mock
Kenneth Walker
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3027642(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL3027642T3 publication Critical patent/PL3027642T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
PL14752711T 2013-07-31 2014-07-31 Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) PL3027642T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31
PCT/US2014/049254 WO2015017710A1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs
EP14752711.3A EP3027642B1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number Publication Date
PL3027642T3 true PL3027642T3 (pl) 2021-01-11

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14752711T PL3027642T3 (pl) 2013-07-31 2014-07-31 Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)

Country Status (35)

Country Link
US (3) US9862752B2 (pl)
EP (2) EP3763734A1 (pl)
JP (4) JP6509852B2 (pl)
KR (3) KR20240000642A (pl)
CN (2) CN113527512A (pl)
AP (1) AP2016009011A0 (pl)
AR (1) AR097181A1 (pl)
AU (1) AU2014296107B2 (pl)
BR (1) BR112016002213A2 (pl)
CA (1) CA2918624C (pl)
CL (1) CL2016000249A1 (pl)
CR (1) CR20160097A (pl)
CY (1) CY1123836T1 (pl)
DK (1) DK3027642T3 (pl)
EA (2) EA037355B1 (pl)
ES (1) ES2828670T3 (pl)
HK (1) HK1225738A1 (pl)
HU (1) HUE050630T2 (pl)
IL (1) IL243749B (pl)
JO (1) JO3566B1 (pl)
LT (1) LT3027642T (pl)
MA (1) MA38873B1 (pl)
MX (2) MX369152B (pl)
NZ (2) NZ754961A (pl)
PE (1) PE20160189A1 (pl)
PH (1) PH12016500208A1 (pl)
PL (1) PL3027642T3 (pl)
PT (1) PT3027642T (pl)
SG (1) SG11201600713RA (pl)
SI (1) SI3027642T1 (pl)
TN (1) TN2016000035A1 (pl)
TW (1) TWI648401B (pl)
UA (1) UA116665C2 (pl)
UY (1) UY35686A (pl)
WO (1) WO2015017710A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US9714276B2 (en) * 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2918624C (en) 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) * 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
BR112016029848A2 (pt) 2014-06-24 2017-10-24 Novo Nordisk As proteínas de fusão mic-1 e utilizações das mesmas
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
NZ730054A (en) 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
BR112018068898A2 (pt) 2016-03-31 2019-01-22 Ngm Biopharmaceuticals Inc anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
JP7058670B2 (ja) * 2018-04-09 2022-04-22 アムジエン・インコーポレーテツド 増殖分化因子１５融合タンパク質
BR112020026432A2 (pt) * 2018-07-13 2021-03-23 Genmab A/S variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso
PE20211078A1 (es) 2018-10-22 2021-06-09 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas
CN113767112A (zh) * 2019-04-23 2021-12-07 株式会社Lg化学 包含免疫球蛋白Fc区和GDF15的融合多肽
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
US20230002460A1 (en) * 2019-11-26 2023-01-05 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
CA3165846A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115244076B (zh) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CA3226178A1 (en) * 2021-08-24 2023-03-02 Jiangyu YAN Gdf15 fusion proteins and uses thereof
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2005047336A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co. Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
BRPI0410927A (pt) * 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2561877C (en) 2004-04-13 2017-03-14 St. Vincent's Hospital Sydney Limited Use of mic-1 or modulating agent thereof to modulate appetite or body weight
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101001642A (zh) * 2004-08-12 2007-07-18 惠氏公司 使用gdf－8抑制剂对糖尿病、肥胖症和心血管病的联合治疗
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007058776A2 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
JP2010500876A (ja) * 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2694863A1 (en) 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
CA2740632A1 (en) 2008-10-31 2010-05-06 St. Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
CN103080746B (zh) 2010-08-26 2015-07-15 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3144320B9 (en) * 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2794905B1 (en) * 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
US9714276B2 (en) * 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CA2862516C (en) * 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
SG10201913376XA (en) * 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
AR094271A1 (es) 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
CA2918624C (en) 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US20170107248A1 (en) 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
BR112016029848A2 (pt) 2014-06-24 2017-10-24 Novo Nordisk As proteínas de fusão mic-1 e utilizações das mesmas
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
KR20160038896A (ko) 2016-04-07
EA037355B1 (ru) 2021-03-17
CA2918624A1 (en) 2015-02-05
AR097181A1 (es) 2016-02-24
MA38873A1 (fr) 2017-09-29
SG11201600713RA (en) 2016-02-26
CY1123836T1 (el) 2022-03-24
CR20160097A (es) 2016-07-29
MX2016001164A (es) 2016-07-26
US20180079790A1 (en) 2018-03-22
NZ717030A (en) 2022-04-29
IL243749A0 (en) 2016-04-21
JP2016532690A (ja) 2016-10-20
CN105980400B (zh) 2021-05-07
EP3027642A1 (en) 2016-06-08
ES2828670T3 (es) 2021-05-27
EP3027642B1 (en) 2020-08-19
EA201690297A1 (ru) 2016-06-30
TN2016000035A1 (en) 2017-07-05
TWI648401B (zh) 2019-01-21
US10894814B2 (en) 2021-01-19
PH12016500208B1 (en) 2016-04-25
UY35686A (es) 2015-01-30
PE20160189A1 (es) 2016-05-06
TW201602345A (zh) 2016-01-16
PT3027642T (pt) 2020-10-30
DK3027642T3 (da) 2020-11-02
CN113527512A (zh) 2021-10-22
MX2019012848A (es) 2019-11-28
JP2019178132A (ja) 2019-10-17
CN105980400A (zh) 2016-09-28
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
MX369152B (es) 2019-10-30
JP6877478B2 (ja) 2021-05-26
PH12016500208A1 (en) 2016-04-25
AP2016009011A0 (en) 2016-01-31
CL2016000249A1 (es) 2016-07-22
CA2918624C (en) 2024-02-13
BR112016002213A2 (pt) 2017-08-29
HUE050630T2 (hu) 2020-12-28
JO3566B1 (ar) 2020-07-05
JP2021113219A (ja) 2021-08-05
AU2014296107B2 (en) 2018-07-26
SI3027642T1 (sl) 2020-11-30
AU2014296107A1 (en) 2016-02-04
JP2023116723A (ja) 2023-08-22
WO2015017710A1 (en) 2015-02-05
HK1225738A1 (zh) 2017-09-15
IL243749B (en) 2018-06-28
KR102376451B1 (ko) 2022-03-23
KR20240000642A (ko) 2024-01-02
JP6509852B2 (ja) 2019-05-08
EA202092386A1 (ru) 2021-04-30
UA116665C2 (uk) 2018-04-25
US20160168213A1 (en) 2016-06-16
MA38873B1 (fr) 2018-11-30
EP3763734A1 (en) 2021-01-13
US20210079051A1 (en) 2021-03-18
NZ754961A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
HK1225738A1 (zh) 生長分化因子15(gdf-15)構建體
HRP20190502T1 (hr) Afukozilirana anti-fgfr2iiib protutijela
IL233725A0 (en) Growth and differentiation factor 15 (gdf-15) polypeptides
HK1203357A1 (en) Fibroblast growth factor 21 proteins 21
GB2530923B (en) Smart shaker room
GB201302597D0 (en) Novel Synthetic Proteins
HK1219961A1 (zh) 人抗α型干擾素抗體
SI3016977T1 (sl) Humana protitelesa proti IL-32
EP3511466C0 (en) LEMINSCATE SHAPED WINDINGS
GB201312513D0 (en) 2 4 1 Technology
GB201304642D0 (en) 02 Planter
GB201322568D0 (en) Taggstar 1
AU350589S (en) Joiner (2)
AU350588S (en) Joiner (1)
GB201308820D0 (en) Part 3 under
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270